Public Employees Retirement System of Ohio Trims Stake in Supernus Pharmaceuticals, Inc. $SUPN

Public Employees Retirement System of Ohio cut its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 96.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 522 shares of the specialty pharmaceutical company’s stock after selling 16,403 shares during the period. Public Employees Retirement System of Ohio’s holdings in Supernus Pharmaceuticals were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in SUPN. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $21,908,000. Assenagon Asset Management S.A. purchased a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $27,428,000. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Supernus Pharmaceuticals by 2,847.0% in the first quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock valued at $19,498,000 after acquiring an additional 364,413 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have commented on SUPN shares. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Trading Down 0.3%

Shares of SUPN stock opened at $46.76 on Friday. The business’s fifty day simple moving average is $46.14 and its 200-day simple moving average is $48.94. The company has a market cap of $2.72 billion, a PE ratio of -24.35, a PEG ratio of 0.80 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12-month low of $40.26 and a 12-month high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.